文献类型：期刊文献

英文题名：Effectiveness of Inactivated COVID-19 Vaccines against COVID-19 Caused by the SARS-CoV-2 Delta and Omicron Variants: A Retrospective Cohort Study

作者：Hua, Qiaoli[1];Zheng, Danwen[2,3];Yu, Bo[4];Tan, Xinghua[5];Chen, Qiumin[6];Wang, Longde[7];Zhang, Jing[8];Liu, Yuntao[2,3];Weng, Heng[9,10];Cai, Yihang[1];Xu, Xiaohua[2,3];Feng, Bing[11];Zheng, Guangjuan[11];Ding, Banghan[2,3];Guo, Jianwen[3,9,10];Zhang, Zhongde[2,3,9]

第一作者：Hua, Qiaoli

通信作者：Zhang, ZD[1];Guo, JW[2];Zhang, ZD[2];Guo, JW[3];Zhang, ZD[3];Guo, JW[4]

机构：[1]Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou 510006, Peoples R China;[2]Guangzhou Univ Chinese Med, Dept Emergency, Affiliated Hosp 2, Guangzhou 510120, Peoples R China;[3]Guangdong Prov Key Lab Res Emergency Tradit Chine, Guangzhou 510120, Peoples R China;[4]2 Peoples Hosp Lanzhou, Dept Gen Surg, Lanzhou 730030, Peoples R China;[5]Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Dept Tradit Chinese Med, Guangzhou 510060, Peoples R China;[6]Xiamen Univ, Dept Tradit Chinese Med, Affiliated Hosp 1, Xiamen 361022, Peoples R China;[7]Gansu Univ Tradit Chinese Med, Affiliated Hosp, Lanzhou 730020, Peoples R China;[8]Xiamen Hosp Tradit Chinese Med, Dept Resp & Crit Care Med, Xiamen 361000, Peoples R China;[9]State Key Lab Dampness Syndrome Chinese Med, Guangzhou 510120, Peoples R China;[10]Guangzhou Univ Chinese Med, Dept Neurol, Affiliated Hosp 2, Guangzhou 510120, Peoples R China;[11]Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Pharmacol Tradit Chinese Med, Guangzhou 510120, Peoples R China

第一机构：Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou 510006, Peoples R China

通信机构：[1]corresponding author), Guangzhou Univ Chinese Med, Dept Emergency, Affiliated Hosp 2, Guangzhou 510120, Peoples R China;[2]corresponding author), Guangdong Prov Key Lab Res Emergency Tradit Chine, Guangzhou 510120, Peoples R China;[3]corresponding author), State Key Lab Dampness Syndrome Chinese Med, Guangzhou 510120, Peoples R China;[4]corresponding author), Guangzhou Univ Chinese Med, Dept Neurol, Affiliated Hosp 2, Guangzhou 510120, Peoples R China.

年份：2022

卷号：10

期号：10

外文期刊名：VACCINES

收录：;Scopus(收录号：2-s2.0-85140905266);WOS:【SCI-EXPANDED(收录号:WOS:000873816600001)】；

基金：This research was funded by National Key Research and Development Program of China (No. 2022YFC0867400, 2020YFA0708001), Collaborative innovation team project of Guangzhou University of Chinese Medicine (2021XK06, 2021XK49), and National Administration of Traditional Chinese Medicine (Nos. 2021ZYLCYJ04-1, 2021ZYLCYJ04-2, and 2021ZYLCYJ07-2).

语种：英文

外文关键词：coronavirus disease 2019; the Delta variant; the Omicron (BA.2.38) variant; inactivated COVID-19 vaccine; a retrospective cohort study

摘要：Background: Real-world evidence on the effectiveness of inactivated vaccines against the Delta and Omicron (BA.2.38) variants remains scarce. Methods: A retrospective cohort study was conducted to estimate the adjusted vaccine effectiveness (aVE) of one, two, and three doses of inactivated vaccines in attenuating pneumonia, severe COVID-19, and the duration of viral shedding in Delta and Omicron cases using modified Poisson and linear regression as appropriate. Results: A total of 561 COVID-19 cases were included (59.2% Delta and 40.8% Omicron). In total, 56.4% (184) of Delta and 12.0% (27) of Omicron cases had COVID-19 pneumonia. In the two-dose vaccinated population, 1.4% of Delta and 89.1% of Omicron cases were vaccinated for more than 6 months. In Delta cases, the two-dose aVE was 52% (95% confidence interval, 39-63%) against pneumonia and 61% (15%, 82%) against severe disease. Two-dose vaccination reduced the duration of viral shedding in Delta cases, but not in booster-vaccinated Omicron cases. In Omicron cases, three-dose aVE was 68% (18%, 88%) effective against pneumonia, while two-dose vaccination was insufficient for Omicron. E-values were calculated, and the E-values confirmed the robustness of our findings. Conclusions: In Delta cases, two-dose vaccination within 6 months reduced pneumonia, disease severity, and the duration of viral shedding. Booster vaccination provided a high level of protection against pneumonia with Omicron and should be prioritized.